Bristol Myers Squibb

Company

Last mentioned: 4d ago

Stories mentioning Bristol Myers Squibb 2

pharma Neutral

Halozyme Q4 2025: ENHANZE Royalty Growth and Opdivo SC Launch Outlook

Halozyme Therapeutics reported robust Q4 2025 results, driven by record royalty revenue from its ENHANZE drug-delivery platform and key partnerships with Roche and Argenx. The company is positioning 2026 as a transformative year, centered on the high-stakes commercial launch of subcutaneous Opdivo in collaboration with Bristol Myers Squibb.

3 sources
pharma Bearish

Halozyme Revenue Beats Estimates Amidst Massive $2.44 EPS Miss

Halozyme Therapeutics reported a strong revenue beat of $451 million for the fourth quarter, driven by its ENHANZE platform royalties, yet surprised investors with a significant non-GAAP EPS miss of $2.44. The discrepancy suggests substantial one-time charges or strategic shifts that contrast with the company's robust top-line growth.

3 sources